Daniel Lynch Sells 21,800 Shares of Blueprint Medicines Corp. (BPMC) Stock
Blueprint Medicines Corp. (NASDAQ:BPMC) Director Daniel Lynch sold 21,800 shares of the business’s stock in a transaction on Thursday, October 13th. The stock was sold at an average price of $30.02, for a total value of $654,436.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Blueprint Medicines Corp. (NASDAQ:BPMC) traded down 2.86% during mid-day trading on Monday, reaching $28.90. The company’s stock had a trading volume of 369,236 shares. Blueprint Medicines Corp. has a one year low of $13.04 and a one year high of $30.90. The stock’s 50 day moving average is $28.13 and its 200 day moving average is $21.91. The firm’s market cap is $786.86 million.
Blueprint Medicines Corp. (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.03. The business had revenue of $7.07 million for the quarter, compared to analysts’ expectations of $4.41 million. Blueprint Medicines Corp. had a negative return on equity of 46.01% and a negative net margin of 284.85%. The company’s revenue for the quarter was up 163.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.81) earnings per share. On average, analysts anticipate that Blueprint Medicines Corp. will post ($3.05) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/daniel-lynch-sells-21800-shares-of-blueprint-medicines-corp-bpmc-stock.html
Hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its stake in shares of Blueprint Medicines Corp. by 0.4% in the second quarter. FMR LLC now owns 4,085,600 shares of the company’s stock valued at $82,733,000 after buying an additional 15,615 shares during the last quarter. BVF Inc. IL boosted its stake in Blueprint Medicines Corp. by 9.7% in the second quarter. BVF Inc. IL now owns 2,895,251 shares of the company’s stock worth $58,629,000 after buying an additional 255,000 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Blueprint Medicines Corp. by 46.8% in the second quarter. BlackRock Fund Advisors now owns 871,793 shares of the company’s stock worth $17,654,000 after buying an additional 277,781 shares in the last quarter. Vanguard Group Inc. boosted its stake in Blueprint Medicines Corp. by 7.4% in the second quarter. Vanguard Group Inc. now owns 566,995 shares of the company’s stock worth $11,481,000 after buying an additional 39,253 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Blueprint Medicines Corp. by 13.4% in the first quarter. Wellington Management Group LLP now owns 536,416 shares of the company’s stock worth $9,682,000 after buying an additional 63,415 shares in the last quarter. Institutional investors and hedge funds own 73.65% of the company’s stock.
BPMC has been the topic of several research analyst reports. Zacks Investment Research upgraded Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research note on Thursday, August 11th. Cowen and Company restated a “buy” rating on shares of Blueprint Medicines Corp. in a research note on Tuesday, August 9th. Canaccord Genuity initiated coverage on Blueprint Medicines Corp. in a research note on Friday, August 5th. They set a “buy” rating and a $26.00 target price on the stock. TheStreet upgraded Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research note on Friday, July 29th. Finally, Wedbush restated an “outperform” rating and set a $41.00 target price on shares of Blueprint Medicines Corp. in a research note on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $30.00.
About Blueprint Medicines Corp.
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.
Receive News & Ratings for Blueprint Medicines Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp. and related companies with MarketBeat.com's FREE daily email newsletter.